( ntial clinical development candidate. ...)Lexicon Develops Antibodies That Lower Triglycerides and,Cholesterol as Potential New Therapy for Heart Disease,Health

    Editor's Notes:

    -- The article, "Lipid-lowering effects of anti-angiopoietin-like 4

       antibody recapitulate the lipid phenotype found in angiopoietin-like 4

       knockout mice," may be found on the PNAS website at http://www.pnas.org

       and downloaded by subscribers or purchased through the Academy's short-

       term access program.

    -- For more information on Lexicon's alliance with Genentech, please visit

       the Lexicon website at http://www.lexpharma.com and select the tab,

       Alliances.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's research and development of ANGPTL4 mAbs and the potential therapeutic and commercial potential of ANGPTL4 mAbs. This p
'"/>